Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01089868

Recruitment Status : Completed

First Posted : March 19, 2010

Last Update Posted : August 7, 2012

Sponsor:

Collaborator:

Deutsche Krebshilfe e.V., Bonn (Germany)

Information provided by (Responsible Party):

Bogdana Suchorska, Ludwig-Maximilians - University of Munich

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	June 2011
Actual Study Completion Date :	July 2012

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ingrisch M, Schneider MJ, Nörenberg D, Negrao de Figueiredo G, Maier-Hein K, Suchorska B, Schüller U, Albert N, Brückmann H, Reiser M, Tonn JC, Ertl-Wagner B. Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma. Invest Radiol. 2017 Jun;52(6):360-366. doi: 10.1097/RLI.0000000000000349.

To Top